Product Description
Apitolisib is an orally available agent targeting phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Apitolisib inhibits both PI3K kinase and mTOR kinase, which may result in tumor cell apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apitolisib)
Mechanisms of Action: PI3K Inhibitor,mTOR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Prostate Cancer|Renal Cell Carcinoma|Endometrial Cancer
Phase 1: Oncology Solid Tumor Unspecified|Lymphoma, Non-Hodgkin|Healthy Volunteers|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2010-023763-17 | P2 |
Completed |
Breast Cancer |
2016-04-07 |
|
| GDC4950g | P2 |
Completed |
Breast Cancer |
2016-04-01 |
|
| GO27983 | P2 |
Completed |
Prostate Cancer |
2015-09-01 |
|
| 2011-000493-56 | P2 |
Completed |
Renal Cell Carcinoma |
2015-06-23 |